Although the search for disease biomarkers continues, the clinical return has thus far been disappointing. The complexity of the body's response to disease makes it difficult to represent this response with only a few biomarkers, particularly when many are present at low levels. An alternative to the typical reductionist biomarker paradigm is an assay we call an "immunosignature." This approach leverages the response of antibodies to diseaserelated changes, as well as the inherent signal amplification associated with antigen-stimulated B-cell proliferation. To perform an immunosignature assay, the antibodies in diluted blood are incubated with a microarray of thousands of random sequence peptides. The pattern of binding to these peptides is the immunosignature. Because the peptide sequences are completely random, the assay is effectively disease-agnostic, potentially providing a comprehensive diagnostic on multiple diseases simultaneously. To explore the ability of an immunosignature to detect and identify multiple diseases simultaneously, 20 samples from each of five cancer cohorts collected from multiple sites and 20 noncancer samples (120 total) were used as a training set to develop a reference immunosignature. A blinded evaluation of 120 blinded samples covering the same diseases gave 95% classification accuracy. To investigate the breadth of the approach and test sensitivity to biological diversity further, immunosignatures of >1,500 historical samples comprising 14 different diseases were examined by training with 75% of the samples and testing the remaining 25%. The average accuracy was >98%. These results demonstrate the potential power of the immunosignature approach in the accurate, simultaneous classification of disease.
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cancer diagnostic | immunodiagnostic | antibody biomarker | peptide microarray C ancer is the most likely disease for which an early diagnostic would be immediately beneficial. Unfortunately, finding specific biomarkers, especially for cancer, has been complicated by the fact that biological molecules (RNA, DNA, proteins, or peptides) that are uniquely released by a small tumor into the bloodstream are extremely dilute. Classical biomarker assays are based on one-to-one molecular recognition events to detect one or a few specific analytes that are often measured by antibodyprotein interactions. There are three fundamental limitations with this approach, all of which are confounded by the dilution problem alluded to above. The first is that the cross-reactivity of such interactions poses a formidable problem in distinguishing diseases. Biology's promiscuous use of a limited number of homologous sequences, folds, and domains makes specificity difficult. The second is that diseases such as cancer are themselves heterogeneous, and individual response to disease, at a molecular level, can vary considerably. It is unlikely that this level of complexity can be quantitatively assessed by one or a few specific proteins or metabolites in a way that supports robust diagnosis. Third, many of the biomarkers that have been proposed are of low stability or require substantial preassay purification or preparation; these aspects introduce substantial variation into the measured values (1, 2) . As a result, although considerable effort has been put into the development of biomarkers, only a small fraction of candidates make it to clinical practice, and the utility of those that are used is sometimes only modest (3) (4) (5) . Here, we explore the ability of the immunosignature technology to address the ideal of a simple, comprehensive diagnostic for multiple cancers.
An "immunosignature" is the pattern obtained when circulating antibodies in blood are allowed to bind to a large microarray of randomized-sequence peptides affixed to a solid surface (6) . Cancers generate neoantigens by virtue of their mutagenic nature, and they tend to release native proteins and biomolecules not normally encountered by the immune system (7) (8) (9) . These behaviors can elicit an immune response (6, 10, 11) . By virtue of the tremendous amplification afforded by B-cell replication (12) , the signal elicited by the disease-specific antigens is massively amplified. In fact, a key aspect of the immunosignature assay is that the blood is greatly diluted before application to the array, such that only the antibodies that have been sufficiently amplified give distinct signals (13) .
Another somewhat counterintuitive aspect of the method is that the peptide sequences used on the microarray are purposefully not chosen to represent the natural antigens of the antibodies produced in response to disease. In fact, in the arrays of 10,000 peptides used in this study, the peptide sequences were generated with a random number generator. This enables the same microarray to be used for diagnosis of any disease. Despite using random-sequence peptides, monoclonal antibodies generated from a wide variety of antigens show specific patterns of binding on these arrays, to both cognate and noncognate sequences (14, 15) . Many of the peptides bound by a monoclonal antibody against a known linear epitope have no obvious sequence similarity to that epitope. Most of the peptides thus identified have demonstrated low affinity in solution for the antibody but are retained on the arrays due to avidity created by close spacing of individual peptides (15) .
Significance
Over much of the world, healthcare systems are facing an unprecedented challenge to meet the medical needs of an aging population while controlling costs. The early detection and treatment of diseases that are prevalent in older people is likely to be a key aspect of economically efficient, high-quality healthcare. In the case of cancer, the resection of a stage I or stage II tumor is often effectively a cure. An ideal diagnostic would allow early detection of disease on a single platform that could be used for any disease. Here, we demonstrate that the immunosignature diagnosis platform could potentially meet the universal platform requirement. Ongoing work will address the early detection requirement separately.
An immunosignature of an individual consists of an overlay of the patterns from the binding signals of many of the most prominent circulating antibodies. Some of the binding signals are present in most individuals (whether sick or healthy), and some are unique to an individual, but if the individual has a disease such as a cancer, a subset of the binding signals will be due to disease-associated antigens that are common to most individuals with the disease (16) . An important aspect of this approach is that it senses essentially all antibodies raised to the disease and detects each of the antibodies as separable binding patterns composed of unique molecular recognition elements. This differs from, for example, an ELISA, which might sum the contributions of many different antibodies using a single protein, cell, or virus capsid. Again, from a statistical perspective, the high dimensionality of this readout affords much more specificity than could be obtained from a set of cognate sequences or from an array of the native antigens themselves.
Not only does the use of highly dilute blood and random peptide sequences in the immunosignature assay paradoxically give rise to improved sensitivity and specificity but these aspects of the assay also result in several other unique benefits of the immunosignature approach. Because of the dilution (1:500 in these studies), blood proteins other than antibodies do not significantly bind to the arrays, meaning that there is no sample preparation involved other than dilution (17) . The dilution ensures the assay is sample-sparing. Finally, the assay is diseaseagnostic. The arrays can be used for the simultaneous detection and identification of multiple diseases.
It is simultaneous detection and identification of multiple diseases with a single assay that underlies the true potential of this approach as a disruptive force in healthcare. This, combined with the fact that serum antibodies are robust to handling (17, 18) such that a drop of blood can be sent dried on filter paper through the mail (17) , should enable frequent, inexpensive monitoring for many different diseases. The goal of the current work is to test the multidisease aspect of immunosignatures rigorously. Although the approach has previously been used to discriminate various subtypes of brain cancer (19) , it has not yet demonstrated multiplexed cancer diagnosis. Here, we perform a blinded train/test validation study wherein a group of 120 individuals with five different cancers from various geographic regions was used as a training set to define a multicancer signature. The signature predicted the disease status of a test cohort of equal size and composition. To explore the ability of the approach to discriminate between an even larger set of diseases, 1,516 different individuals spanning 14 different disease cohorts plus a diverse cohort of healthy controls were assayed and the ability to distinguish between these diseases was evaluated.
Materials and Methods
Immunosignaturing Microarrays. The immunosignature peptide microarray used in this work has been described previously (15) . Two different libraries of 10,000 random-sequence, 20-residue peptides were used (each peptide contains 17 variable amino acids and a common 3-aa linker). The two libraries of random-sequence peptides are of completely different sequences. Library version 1 contains 10,420 peptides and was used for trial 1. Library version 2 contains 10,286 peptides and was used for trial 2. Library 1 was printed such that two completely isolated assays are available on one slide but only a single replicate of each sequence is available per assay. Library 2 was printed with duplicate peptides but with only one assay per slide. Peptides for library 1 were synthesized by Sigma Genosys, and those for library 2 were synthesized by Alta Biosciences. A common linker sequence, GSC, was synthesized on the amine terminus of all peptides in library 1 and on the carboxyl terminus in library 2. The variable 17 residues for each peptide in both libraries were determined by a random number generator. Peptides were printed onto aminosilane-coated glass slides (Schott) by Applied Microarrays using noncontact piezo printing.
Assays. Microarrays are preincubated with blocking buffer [BB = 10 mM PBS (pH 7.3), 0.5% BSA, and 0.5% Tween] for 1 h before addition of a 1:500 dilution of serum into sample buffer (SB = BB less 0.5% Tween) for 1 h at 25°C. The primary antibody is washed off with BB, and the peptide-bound antibodies are detected by addition of 5 nM AlexaFluor 647-conjugated anti-human secondary antibody (Rockland Antibodies) for 1 h in SB at 25°C and are then washed three times in SB and five times in 18 MΩ of water, followed by centrifugation at 1,800 × g for 5 min to dry. Arrays are scanned at 10-μm resolution at 647-nm wavelength by an Agilent C scanner using high laser power and 70% gain for the photomultiplier tube. The resulting Tagged Image File Format images are aligned using the corresponding GenePix Array List file which assigns a measured fluorescence intensity to its peptide feature. All data are publicly available in the Gene Expression Omnibus (GEO) in superseries GSE52582, which contains data from trial 1 (GSE52580) and trial 2 (GSE52581).
Samples. Serum samples were received at Arizona State University through Institutional Review Board Protocol no. 0912004625, "Profiling Biological Sera for Unique Antibody Signatures," which was renewed in March 2013 by the Western Institutional Review Board (Olympia, WA). All patient samples were obtained under informed consent and deidentified by the donating clinic. All disease states were assessed by a trained pathologist in consultation with an oncologist at each clinic. Details of a patient's age, sex, outcome, date of diagnosis, or disease substratification are restricted by the agreement with the donating clinics. However, every effort was made to ensure no patient was undergoing therapeutic antibody treatment. No patients were censored due to age, sex, or subsequent outcome. Table 1 describes the samples for trial 1. Table 2 describes the samples for trial 2. Other than the class designated as "BC second tumor" in trial 2, which only included women who were diagnosed with a new, spontaneous tumor following resection of a primary breast tumor, patients followed the same restrictions for inclusion as used in trial 1. No patients were censored due to age, sex, or subsequent outcome. Collaborators are listed by name in Table 1 In total, 240 serum samples were randomly selected from multiple sites. One hundred twenty unblinded samples were used for training, and 120 blinded samples were tested. Column 1 lists the disease state reported for the training samples, as noted at the time of diagnosis. Any comorbidities were ignored for the purpose of classification. Blinded test samples were kept unknown until completion of the classification process. Column 2 (Training) and column 3 (Test) refer to the total number of unique serum samples. The numbers in parentheses refer to the number of samples from each clinic, respectively, as listed in column 4. Column 4 lists the clinic(s) providing the samples; definitions of abbreviations are provided in Materials and Methods. Brain cancer, lung cancer, and MM samples were available from a single clinic only. The raw data from trial 1 are available for public download in the GEO's public repository (www.ncbi.nlm.nih.gov/geo/) under accession no. GSE52580. The downloadable file for trial 1 lists each serum sample as belonging to one of the six classes listed in column 1, and designated as either "Training" or "Test." MMRC, Multiple Myeloma Research Consortium.
Microarray Data Analysis. For trial 1, three technical replicates for each sample were processed and averaged. Technical replicates with a Pearson's correlation coefficient <0.85 were reprocessed. On average, 10% of the arrays had to be reprocessed due to high background, uneven aminosilane coating, or other image anomalies. Data were median-normalized per array. Initial feature selection in the training set of samples used multiple test-corrected ANOVA. Further filtering was done by pattern matching using "Expression Profile" in GeneSpring 7.3.1 (Agilent) with Euclidean distance/average linkage as the similarity measure. For this filter, each disease group (disease) was compared with all other disease groups (cumulatively referred to as nondisease). Peptides with consistently high signal in disease and consistently low signal in nondisease were chosen as being the most selective for that given disease. This was repeated for every disease until equal numbers of peptides were selected for every disease. For trial 1, 120 peptides from the training set were chosen to classify the five cancers and one control cohort (Table S1 ). For trial 2, 280 peptides from the training set were chosen to classify the 14 diseases and one control cohort (Table S2) . Classification of the test samples was done in R, version 2.6.2, using support vector machine (SVM) as the main classifier, with default parameters. All code used to generate the classification is listed in Dataset S1. To avoid biased results from the choice of classifier, four other classifiers were used (Table S3) , with code included in the Dataset S1. Table 3 contains the SVM results for trial 1 [using the "confusionMatrix" function in the ROCR package (20)], with the corresponding receiver operating characteristic (ROC) plot shown in Fig. S1 as produced by pROC in S+ (Insightful) (21) . Confidence intervals were reported for each of the values (22) . False-positive (FP) results are reported such that there is a corresponding false-negative (FN) result in the missed class.
For trial 2, the size of the dataset dictated a simple and conservative holdout method for training and testing. Leave-one-out cross-validation often underestimates error and leads to overfitting. Therefore, we randomly chose 75 ± 7% of the samples for training, leaving the remaining ∼25% for testing. The 7% variation was designed to simulate differences in natural cohort sizes. This was repeated 100 times, and an average ± 95% confidence interval was reported for accuracy, specificity, sensitivity, positive predictive value, and negative predictive value for each of three different classifiers: linear discriminant analysis (LDA), naive Bayes (NB) and SVM. Table 4 lists the 100-fold holdout results for each disease and each classifier separately. The 95% confidence interval is an indicator of how well each disease is predicted by the chosen peptides. Smaller cohorts demonstrated higher variance, because each sample had greater relative impact on the classification performance. Exactly 280 total features were selected per iteration. There were 197 features in common across all 100 training iterations.
Study Design. Trial 1. A blinded test-train trial was created using three technical replicates of 120 unblinded training samples representing five different cancers plus controls. An equivalently sized test cohort was created by using samples that remained blinded by the collaborator. Collection site, collection date, age, and sex were randomized. Samples were serum or plasma (17) from venous draws of 2-10 mL each, stored at −20°C. Initial patient consent was obtained by each clinic independently. Due to differences in patient protocols across clinics, this report can only provide the disease class as reported to ASU by the pathologist and oncologist for each clinic. Trial 2. To reveal any underlying sensitivity to extraneous factors, such as collection site, microarray manufacturing variance, and sample processing, 2,118 samples from 10 different collaborators were processed between September 2007 and January 2011. This large and diverse sera bank contains samples from more geographical locations than trial 1 and contains uneven In total, 1,516 serum samples were used in trial 2. For each class listed in column 1 (Disease state), the total number of unique samples for that disease is listed in column 2 (Disease cohort). A 100-fold resampling method selected 75 ± 7% of the samples from each disease class for training, with the remaining held back for testing. This reselection process was done 100 times. The average and SD of the test size are listed in column 3 (Test size). Collaborators who donated the samples are listed in column 4; definitions of abbreviations are provided in Materials and Methods. The raw data from trial 2 are available for public download in the GEO's public repository (www.ncbi.nlm.nih.gov/geo/) under accession no. GSE52581. The downloadable file for trial 2 lists each serum sample as belonging to one of the 15 classes in column 1. Table 3 . Classification scores for trial 1 using SVM True calls and miscalls are listed in the gray area of the chart. All performance statistics are calculated from these calls and are listed in the white area. Average accuracy is 0.95, with a 95th percentile confidence interval of 0.8943, 0.9981(kappa = 0.94). Note that any missed call (FN) for a given class would yield a simultaneous FP call in another class, because all samples must be either a true call or a miscall. BrC, brain cancer, ND, nondisease; NPV, negative predictive value; PPV, positive predictive value. Statistics in the lower part of the graph are calculated using confusionMatrix (R 2.6.2, package "carat"). The code for analysis is provided in Dataset S1.
numbers of patients per disease with unequal distributions of age, sex, ethnicity, and reported comorbidities. Microarrays are subject to a number of technical issues, including image artifacts that can affect the resulting data quality. We examined the 2,118 microarrays and reduced the total number of samples to 1,922 by eliminating those samples whose technical replicates had a Pearson's correlation coefficient <0.85. Most failures resulted from gross image artifacts, such as high background, uneven aminosilane deposition, and scratches or other surface defects. No sample was used without a technical replicate to estimate reproducibility; therefore, 21 samples were subsequently excluded because their replicate was removed. We then examined the remaining microarrays for signs of microarray batch bias using ComBat (23, 24) . Because each microarray was printed in batches, it was possible that a printing failure could result in low-quality arrays or arrays that did not match previously manufactured arrays. In total, 406 arrays were removed due to manufacturing batch-bias that exceeded the disease-related signal. No disease class lost significantly more samples than another. The remaining 1,516 samples were used for holdout testing.
Results
Trial 1. The primary goal of this effort was to determine the capability of immunosignatures to classify multiple diseases. This issue was explored in two separate trials. In trial 1, equal numbers Approximately 75% of each class was removed for training, with 25% held out for testing using these different classifiers. This was done 100 times, and the results from LDA (yellow), NB (red), and SVM (green) classifications are shown as the average from the 100 different tests, with the 95th percentile confidence interval displayed.
of training and test samples were collected from multiple sites ( Table 1 ) and used in a train/blinded test format. In the training phase, 20 sera samples from each of six cohorts were used: (i) patients with advanced pancreatic cancer (PC), (ii) therapy-naive glioblastoma multiforme (GBM; an aggressive form of astrocytoma), (iii) esophageal adenocarcinoma (EC), (iv) multiple myeloma (MM), (v) stage IV breast cancer (BC), and (vi) mixed "nondisease" controls. The nondisease controls were obtained from collaborating clinics, as well as healthy samples collected locally. These sample cohorts were assayed and used to define the signatures for each disease.
Assays were performed as described in Materials and Methods. Each assay was performed in duplicate, and the average Pearson's correlation coefficient between replicates for all 120 samples in the training set was 0.92 ± 0.05. BC demonstrated the lowest average replicate correlation (0.87), and EC demonstrated the highest (0.96). We first performed a t test between each of the n = 20 cancer cohorts and the n = 20 control cohort, one by one. The number of peptides with P < 9.6 × 10 −5 is listed in Table 5 , along with the minimum P value obtained. In each case, there were at least 600 and typically >1,000 peptide features with P < 9.6 × 10 −5
. The minimum P value in each case was more the six orders of magnitude smaller than random chance would predict, implying that the separation between each disease and healthy controls was statistically sound. The sensitivity in distinguishing each sample ranged from 80-100%, with PC having the lowest sensitivity. The specificity was greater than 98% for each diagnosis. In a pairwise test against control patients, MM displayed the most significantly different peptides by t test, at 3.25 × 10 −34 . Of the top 100 peptides selected in this way, only BC showed no overlap with any other disease.
The analysis described above indicates that a signature distinguishing each cancer from noncancer controls can be established. Clinically, it would also be relevant to be able to distinguish each cancer from the other types. In the analysis described above, there was overlap in the signatures distinguishing each cancer from noncancer, as shown in the rightmost column of Table 5 . In the case of BC, the top 100 peptides that distinguished it from healthy controls via t test were completely unique (i.e., none of those peptides appeared in the top 100 peptides of any other disease); however, for GBM, 26 peptides appeared at least once in another list. This implies that greater stringency is required to obtain sufficiently high specificity in a multiclass analysis than can be obtained by t test.
To assess the performance of multiple classifications, multiclass peptide feature selection was performed as described in Materials and Methods. Twenty-four of the most distinguishing peptides per disease were selected for a total of 120 peptides in the final feature set. PC and BC had relatively low overall signals, whereas EC and brain cancer had much higher signals. Therefore, it was important to perform the feature selection in such a way that the classifier is not overwhelmed by diseases with stronger average signal strength (Materials and Methods). A leave-one-out cross-validation of the training set produced only two miscalls of 120 calls when using SVM as a classifier.
The blinded test set consisted of 20 samples from each of the six cohorts. These samples were held blinded by collaborators until the analysis was complete. Nondisease controls were selected at random from a mixture of blinded controls from collaborators, as well as internally blinded, locally collected healthy controls (distribution of collection sites is shown in Table 1 ). The test dataset was classified using the 120 peptides obtained from the training described above with SVM as the classifier. The results are shown in Table 3 , with the associated ROC curve shown in Fig. S1 . Visualization of the relative group-wise separation is shown in Fig. 1 for each of the tested classifiers (SVM is coded in orange and is always listed first). To calculate FP and FN results, any sample that was incorrectly called was counted as an FP result for the called disease and counted as an FN result for the cohort to which it actually belonged. Even using this stringent scoring approach, with the exception of PC, the sensitivity was greater than or equal to 95% (80% for PC) using SVM. The specificity for all cancers was at least 98% using SVM. The low sensitivity for PC may be due to general immune suppression in later stages of this disease (16, 25, 26) .
To test the analysis for dependence on a particular type of classifier, we examined four other classifiers in addition to SVM (Table S3 and Figs. S2-S5 for the ROC charts and Fig. 1 , Upper and Lower, for each classifier's group-wise separation). No classifier or feature set was optimized to increase accuracy. Of the classifiers tested, SVM gave the best results and principal component analysis (PCA) gave the worst results, particularly in terms of sensitivity. This is not surprising, because the hyperplanes associated with the SVM algorithm allow for a more accurate description of multidimensional (many disease cohorts) data space than a methodology like PCA that attempts to describe the dataset as a minimum number of components (additional details of classifier performance and limitations are provided in SI Text).
To give a visual indication of the intensity data and disease differences resulting from trial 1, Fig. 2 shows a heat map of the 120 feature-selected peptides (y axis) and 120 patients (x axis) ordered by divisive hierarchical clustering using Euclidean distance with average linkage to estimate node separation. This hierarchy is explicitly depicted in the colored dendrogram (Fig.  2, Left) . In Fig. 2 , the results from a k-means clustering of the peptides, where k = 5 classes (shown as I to V), are listed to the right of each heat map. The noncancer controls were not used to select nondisease peptides; thus, there were five groups of peptides and six groups of patients. One heat map (Fig. 2, Left) shows the training dataset using the 120 selected features, and the other heat map (Fig. 2, Right) shows the unblinded test data clustered using the same 120 peptides.
In trial 1, the fact that signals from 10,000 peptide features were used to select a small subset of features that discriminated the five diseases and healthy controls might give rise to overfitting if the analysis was done incorrectly. The blinded test analysis verified that there was no pure statistical overfitting of the cohorts, as one might get by selecting features from data dominated by random noise. However, one might still be concerned that the discrimination seen was not for the disease but for other aspects of the sample cohorts. It was therefore important to exclude the possibility of fitting to a particular sample collection, whether the protocol, the geographical location, the 
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A standard t test using multiple testing correction (familywise error rate = 5%) was used to compare the 20 training samples from trial 1 for each disease against the single set of 20 noncancer controls, as a binary comparison. Column 1 lists the disease cohort. Column 2 lists the number of peptides with a P value <9.6 × 10 −5 (corresponding to one FP result per 10,480 peptides). Column 3 is the minimum P value calculated for each pairwise comparison. Column 4 is the number of peptides of the top 100 most significant that overlap with peptides from at least one other disease, used as a test for specificity. BC had no overlap with any other disease, whereas GBM overlapped with peptides from three different diseases. NA, not applicable.
patient population, or the manner in which the sample was stored. To control for this, training and test samples for two of the diseases were randomly selected from three sites (BC and PC; Table 1 ). More importantly, the healthy controls were selected from four sites. Thus, if sample-specific problems were an issue, one would have expected that some of the 20 healthy controls would have been miscalled. In fact, all 20 of the healthy controls were called correctly (Table 3) , making it unlikely that nonbiological factors dominated the classification performance.
Trial 2. One of the more important results from trial 1 is that a signature can be defined that accurately detects and identifies a complex and heterogeneous disease, such as stage IV BC relative to healthy controls and four other cancers. We wanted to extend this idea by asking how many different diseases could be distinguished on this type of array. Trial 2 was designed to explore this question. The number of diseases was increased from five to 14, and the number of total samples was increased from 120 to over 1,500. Also included separately are several different types of brain cancers, two cohorts of early BC by stage, and a cohort of BC that involves a new occurrence of a tumor (not a metastasis). In addition, PC and pancreatitis are included so that two distinct diseases of the same organ are present. The question was whether disease heterogeneity limited the number of diseases that could be distinguished, at least with arrays of 10,000 peptides. Table 2 describes the samples used in the 1,516-sample cohort. From each disease sample set, 75% of test samples were randomly selected as the training set as described in Materials and Methods, and feature selection and training were performed using these samples independent of the test samples. The remaining 25% of test samples were then called based on the resulting signature. This random resampling, training, and testing were repeated 100 times. Fig. 3 is a heat map depicting the binding intensity associated with 280 classifier peptides from one of the feature sets arising from resampling (Materials and Methods) across the entire 1,516-patient sample set, with cohort size listed in parenthesis. The colors in Fig. 3 distinguish high (red) from low (blue) intensities, and the patterns that remain after hierarchical clustering of both peptides (y axis) and patients (x axis) help to visualize the relative difference within and across disease cohorts. Fig. 4 illustrates the ways by which individual peptides contribute to the overall disease classification performance. Table 4 displays the average results of the resampling conducted 100 times using an SVM classifier (Materials and Methods). The average accuracy of assigning the test cohort was 97% or greater for each disease and healthy controls, in support of the thesis that distinct signatures can be determined for each of the disease cohorts even in the background of such a varied and complex set of samples. Table 4 includes results for two other classifiers (LDA and NB), which were similar. We conclude that 10,000 peptides used to develop immunosignatures may be able to distinguish up to 15 different disease conditions.
Discussion
We first established signatures for five different cancers relative to noncancer controls, using 20 known training samples for each disease. This was done using a case vs. control method for each disease vs. nondisease controls. The signatures thus created were able to classify the blinded test set with less than perfect specificity. Using this type of pairwise feature selection method led to overlap in the peptides designed to classify the different cancer types. To distinguish each cancer optimally, peptides were selected to optimize multiclass separation. Peptides were selected from the training set using a more stringent process, reducing the overlap in peptides to zero. Greater than 95% accuracy was obtained when testing the 120 blinded samples. The rigor of this type of analysis was extended in a second trial involving 14 disease classes and a nondisease control group using 1,516 different samples. Seventy-five percent of the samples for each disease class were used for training, following the same selection process as the first trial, with the remaining 25% used as the test set. The process was repeated 100 times to arrive at overall accuracy. The sensitivity for each disease group was >95%, except for PC (80%), and the overall specificity was 95%.
With 10 9 different circulating antibodies in the blood (27) , it may seem remarkable that the signature of antitumor antibodies is detectable. It is clear that B cells respond to tumors at early stages (26, 28, 29) . Antibodies to both self-antigens and neoantigens are Table 3 for SVM and in Table S3 Fig. 1 . The values for each of the 120 peptides and 120 patient samples are plotted with blue, indicating low binding, and with red, indicating high binding. Hierarchical clustering using Euclidean distance as the measure of similarity was used to cluster the peptides (y axis) and patients (x axis). The hierarchy to the far left is based on this clustering result. The colored bars to the right were created by k-means clustering using five clusters.
induced. Both nucleic acid-encoded and nonencoded antigens (e.g., glycosylated) can elicit a B-cell response. The results we report indicate that antibodies unique to each type of tumor can bind to the array and be discerned from other antibodies. Presumably, neoantigens would elicit higher affinity antibodies than self-antigens or natural antibodies (30) , which is an important presumption, given that we have demonstrated a highaffinity monoclonal antibody can be diluted 100-fold into healthy serum without diminishing the signal of the monoclonal antibody (15) . This implies that high-affinity antibodies (i.e., those elicited by foreign antigens and by antibody maturation) have higher affinity to the random peptides than low-affinity antibodies. This may, in part, explain the ability to discern the tumorspecific signature. Even though multiple individuals recognize the same tumor-specific antigen, individuals respond to these antigens slightly differently. Immunosignaturing likely detects the unique antibodies that individuals raise against tumor antigens, but the feature selection process excludes peptides that are not common across cohorts with the same disease. This training process is critical to establishing a trustworthy signature that works in a broader population.
Given that the sequencing of thousands of tumors has led to the conclusion that tumor mutations are very specific, it may seem remarkable that a common signature can be discovered for each tumor. The definition of the signature is based on the required distinction between samples. The immunological implications of these common signatures are that each class of tumors presents at least some common antigens to the immune system and each individual makes a similar antibody to that antigen. This antigen can be misproduction or unusual posttranslational modification of a native protein, such as Her2 or MUC1. If the tumors present common protein variants (e.g., frameshift, mutation, posttranscriptional or posttranslational variant), they would also create a common immunosignature. An important implication is that common tumor-specific antigens exist that are not being detected by genomic or transcriptome sequencing.
An unusual feature of the immunosignature procedure is that because it involves a true signature, the training phase also becomes the de facto discovery phase. The implication is that the signature peptides are determined by the distinction required, whether a single disease vs. control or multidisease vs. control. This was evident in trial 1, where the peptides chosen to distinguish each cancer from the control cohort using a pairwise case vs. control method were different from those discerning multiple cancers simultaneously. There may be peptides that react to more than one (Lower) Graph (blue) shows the intensity for peptide FPEILSTTIDRVVVNRGGSC. The y axis is the normalized intensity for each peptide, and the x axis is the patient sera sample with the disease classes split. (Upper) Example shows a peptide with high intensity for three different diseases. This peptide is an example of one that is not perfect for an individual disease but contributes partly to discriminating three of the diseases from the other 11 diseases. (Lower) Example is a peptide that is very high for a single disease and very low for every other disease. These two examples represent how individual peptides contribute to the ability of the classifier to distinguish multiple diseases simultaneously. Disease classes are grouped together and arbitrarily represented by numbers 1-15 rather than the disease name. Group 14 is unlisted due to size constraints.
cancer (see Fig. 4 ), but that knowledge remains undiscovered until the other cancer(s) is tested.
The robustness of the assay becomes apparent by examining the nature of the samples used. All samples came from historical collections, some >10 y old. Additionally, samples were collected from multiple geographical sites, and in trial 2, the size of the cohort could vary and no effort was made to match age, sex, or ethnicity. Using this type of diverse sample set for training demands a robust signature, but also one that is less likely to fail in testing due to overfitting. That the immunosignature technique is apparently robust as well as simple and inexpensive may enhance success with large and diverse training sets. Combined with the ability to use historical samples (17) , the cost of clinical validation of immunosignature diagnostics could be very low by comparison with standard practice. Also, unlike standard biomarker development, the platform for discovery of an immunosignature would be the same as that used in clinical practice. Changes in diagnostics that make them more clinic-friendly often create new performance characteristics that require new evaluations.
A potential value of the immunosignature diagnostic is that the same platform would be used for any type of diagnosis. This feature would drive the cost down, allowing broad use, even for early detection of disease. To meet this objective, independent signatures for multiple diseases would be obtained from the same array. We had previously demonstrated that the same array could signature infections (15), Alzheimer's disease (31, 32) , pancreatic diseases (16) , and four types of brain cancer (19) . However, in trial 2, we significantly expanded the demand for cross-disease distinction. The signatures were chosen to distinguish 14 diseases from each other and from a broad range of noncancer controls. The cancers included three different stages of BC, four different brain cancers, two diseases of the pancreas (only one of which was PC), ovarian cancer, and two different blood cancers. The conclusion was that 10,000 peptides were sufficient to select signatures that could distinguish these serum samples by disease with at least 95% overall accuracy. How many more diseases and how many different types could still be distinguished on 10,000 peptides remain to be seen, because some cancers, such as GBM, yield unique and robust signatures, whereas others, such as PC, are far less distinct. Although 95% accuracy should be sufficient for regular monitoring of major diseases, regular monitoring of less prevalent diseases might require greater performance. We note that the next version of the immunosignature peptide microarrays currently under development has >300,000 peptides.
The immunological implication of the diagnostic distinctions we report here is that each of the disease conditions produces either different antigens and/or different B-cell responses to common antigens. Both would create distinctive antibodies, and therefore distinctive signatures. In the case of cancer, it seems likely that the antigens eliciting the signature B-cell response are made by the tumor cells, but the antigens could also be elicited in nontumor cells. For example, it has been shown that stromal cells around a tumor are genetically altered (33, 34) . We note that the different stages of BC had distinguishing signatures. Perhaps each stage produces a different dominant set of antigens or the B-cell response to the same antigen matures, creating a new signature. The end result is a unique signature, but the underlying process remains unknown.
The peptides on the array are chosen from nonnatural sequence space. This allows the same array to be used for any diagnostic in any species. However, the limitation of this strategy is that one cannot simply align the peptides in the signature to the natural proteomic space to identify the causative antigen. We have demonstrated that under some circumstances, a relevant alignment can be established (14) , and we have developed an algorithm to facilitate this effort (35) , but higher density peptide arrays will be required for routine use of this approach in antigen discovery.
Finally, relative to the ideal diagnostic system, we have shown that immunosignatures offer the potential of a single, simple platform for diagnosing multiple diseases. Another important specification in this regard is the ability to detect disease early (36) . In this regard, immunosignatures may have an advantage over conventional biomarkers because the activated B cell can amplify its signal (specific antibody) 10 11 -fold in 1 wk (12, 37) . We have demonstrated that the immunosignature of Alzheimer's disease in the mouse model can be detected very early (32) and that pancreatic intraepithelial lesions in humans (an early form of ductal pancreatic adenocarcinoma) have distinct signatures (16) . The extent to which this platform can generally be used to detect disease early with adequate specificity requires further investigation.
In summary, we have demonstrated that the immunosignature technology using a 10,000-peptide array is capable of high accuracy in a standard training and blinded test assay, and can be used for the simultaneous classification of multiple cancers. The arrays used in this study are available for purchase (www. peptidearraycore.com). Raw data are available at the GEO (National Center for Biotechnology Information) under superseries accession no. GSE52582.
